原发性肺黏液表皮样癌23例临床病理分析

Pulmonary mucoepidermoid carcinoma: a clinicopathological study of 23 patients

  • 摘要:
    目的 原发性肺黏液表皮样癌(pulmonary mucoepidermoid carcinoma,PMEC)是一种罕见的肺部恶性肿瘤,占所有原发肺肿瘤的0.1%~0.2%,PMEC临床症状及流行病学特征既不特异也不典型,诊断尚存在一定困难。
    方法 收集2012年11月至2023年12月苏州大学附属第一医院的23例PMEC标本,所有病例标本均经病理科系统评估,结合组织形态学特征、免疫组织化学检测(immunohistochemistry,IHC)、荧光原位杂交技术(fluorescence in situ hybridization,FISH)及过碘酸雪夫染色(periodic acid-Schiff stain,PAS)等综合分析,获得明确病理诊断。
    结果 肿瘤由黏液分泌细胞(以下称黏液细胞)、中间型细胞和表皮样细胞3种细胞以不同比例混合组成。免疫表型:瘤细胞CK7主要表达于黏液细胞,CK5/6、p40、p63表达于表皮样细胞及中间型细胞;Ki-67增殖指数5%~60%,TTF-1、Napsin A均阴性,23例行PD-L1(克隆号 22C3)检测,5例阳性,肿瘤比例评分(tumor proportion score,TPS)区间为3%~20%;11例行ALK(克隆号 D5F3)检测均阴性;2例行c-Met免疫组织化学检测,均为弱阳性表达(+);Mastermind样转录共激活因子2(mastermind-like transcriptional coactivator 2,MAML2)基因重排阳性率为34.8%(8/23);黏液细胞PAS染色阳性。Kaplan-Meier生存分析表明,存在淋巴结转移、远处转移、TNM高分期(Ⅲ+Ⅳ期)、低分化以及MAML2阴性的患者预后显著不良。单因素分析结果显示,组织学低分化、淋巴结转移、远处转移及TNM高分期是影响预后的主要危险因素;进一步的多因素分析证实,组织学低分化和远处转移是导致患者预后不良的独立危险因素。
    结论 PMEC是一种侵袭性肿瘤,发病率低,其临床表现缺乏特异性,易导致误诊,在临床诊断过程中需保持高度警惕,并做好鉴别诊断。

     

    Abstract:
    Objective  Primary pulmonary mucoepidermoid carcinoma (PMEC) is a rare malignant lung tumor that accounts for approximately 0.1%–0.2% of all primary pulmonary neoplasms. Due to the non-specific clinical symptoms and epidemiological features, PMEC poses diagnostic challenges.
    Methods  Tissue blocks from 23 archived PMECs were collected from The First Affiliated Hospital of Soochow University (November 2012 to December 2023). To establish definitive diagnoses, comprehensive histopathological evaluation, including histomorphological analysis, immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and periodic acid-Schiff (PAS) staining were performed.
    Results The tumors consisted of varying proportions of mucin-secreting cells (mucous cells), intermediate cells, and epidermoid cells. Immunophenotypically, CK7 was predominantly expressed in the mucous cells, whereas CK5/6, p40, and p63 were expressed in the epidermoid and intermediate cells. The Ki-67 proliferation index ranged from 5% to 60%. All tumors were negative for TTF-1 and Napsin A. Five of the tumors were positive for PD-L1 (clone 22C3), with a tumor percentage score of 3%–20%. All 11 tumors tested for ALK (clone D5F3) were negative. IHC for c-Met was performed on two tumors and both were weakly positive (+). Mastermind-like transcriptional coactivator 2 (MAML2) gene rearrangement was detected in 34.8% (8/23) of the tumors. Mucous cells were PAS positive. Kaplan-Meier survival analysis revealed a significantly poorer prognosis for patients with lymph node metastasis, distant metastasis, advanced TNM stage (Ⅲ+Ⅳ), poor differentiation, or MAML2 gene rearrangement negativity. Univariate analysis identified poor histological differentiation, lymph node metastasis, distant metastasis, and advanced TNM stage as the major prognostic risk factors. Multivariate analysis confirmed poor differentiation and distant metastasis as independent risk factors for adverse outcomes.
    Conclusions PMEC is an aggressive tumor with low incidence and non-specific clinical manifestations, leading to frequent misdiagnosis. Clinicians should maintain a high index of suspicion and ensure a thorough differential diagnosis.

     

/

返回文章
返回